|
|
Tandem Diabetes Care Inc (NASDAQ: TNDM) |
|
Price: $19.1700
$0.99 
5.446%
|
| Day's High:
| $19.28
| Week Perf:
| 5.56 %
|
| Day's Low: |
$ 18.39 |
30 Day Perf: |
-41.75 % |
| Volume (M): |
1,800 |
52 Wk High: |
$ 53.69 |
| Volume (M$): |
$ 34,514 |
52 Wk Avg: |
$37.60 |
| Open: |
$18.46 |
52 Wk Low: |
$17.64 |
|
|
| Market Capitalization (Millions $) |
1,252 |
| Shares
Outstanding (Millions) |
65 |
| Employees |
2,400 |
| Revenues (TTM) (Millions $) |
940 |
| Net Income (TTM) (Millions $) |
-96 |
| Cash Flow (TTM) (Millions $) |
10 |
| Capital Exp. (TTM) (Millions $) |
19 |
Tandem Diabetes Care Inc
Tandem Diabetes Care Inc is a medical device company that is focused on developing and commercializing innovative products for individuals with diabetes. Based in San Diego, California, the company was founded in 2006 and went public in 2013.
Tandem Diabetes Care is primarily known for its insulin pump products, which are small, wearable devices that deliver insulin to people with diabetes. The company's flagship product is the t:slim X2 insulin pump, which was first launched in 2016. This pump uses a touchscreen interface and Bluetooth connectivity to provide patients with real-time data about their insulin delivery and glucose levels. The t:slim X2 also includes software updates that can be downloaded remotely, allowing patients to keep their device up-to-date with the latest features and improvements.
Tandem Diabetes Care has invested heavily in research and development, with a focus on creating products that are easier to use, more accurate, and more effective. The company has also made efforts to improve customer support and education, with a dedicated team of clinical specialists available to help patients learn how to use their devices and manage their diabetes.
In addition to its insulin pump products, Tandem Diabetes Care also offers a range of accessories and supplies, including infusion sets, cartridges, and other items that are needed to use the pump. The company's products are sold in the United States and internationally, with a network of distributors and other partners around the world.
Overall, Tandem Diabetes Care is a leading player in the diabetes care market, with a focus on innovation and customer satisfaction. As the prevalence of diabetes continues to grow globally, the company is well-positioned to serve the needs of patients and healthcare providers, and to continue developing new and improved products in the years ahead.
Company Address: 12400 High Bluff Drive San Diego 92130 CA
Company Phone Number: 366-6900 Stock Exchange / Ticker: NASDAQ TNDM
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Tue, Jan 7 2025 5:32 PM UTC
In a significant move to enhance diabetes management technologies, Tandem Diabetes Care, Inc. has entered a multi-year research collaboration with the University of Virginia Center for Diabetes Technology. The partnership aims to leverage UVA s pioneering advancements in closed-loop insulin delivery systems, which could revolutionize care for individuals living with diabetes...
|
| Business Update
Published Tue, Aug 20 2024 5:35 AM UTC
San Diego Tandem Diabetes Care, Inc. has announced the release of an updated version of its Apple iOS t:connect mobile app, designed specifically for users of the t:slim X2 insulin pump. Scheduled to be available on August 20, 2024, the app update, version 2.8.2, aims to correct battery depletion issues that were highlighted in a nationwide recall issued in March 2024. Us...
|
| Announcement
Published Sat, Aug 10 2024 1:00 AM UTC
In a significant development for investors in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), Bragar Eagel & Squire, P.C., a prominent shareholder rights law firm, has announced that it is investigating potential claims against the company on behalf of long-term stockholders. This scrutiny comes on the heels of a class action complaint lodged against Tandem, dated September 8, 20...
|
| Business Update
Published Mon, Jul 29 2024 2:47 PM UTC
In a significant advancement for diabetes management, Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM) have announced that the t:slim X2 insulin pump integrated with the latest Dexcom G7 Continuous Glucose Monitoring (CGM) system has received authorization for sale from Health Canada. This innovative integration emphasizes a commitment to enhancing t...
|
| Business Update
Published Wed, May 29 2024 1:38 PM UTC
Tandem Mobi Insulin Pump Now Compatible with Dexcom G7 CGM: A Breakthrough in Diabetes Management SAN DIEGO - Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM) today announced a significant advancement in diabetes management, unveiling the full compatibility of the Tandem Mobi insulin pump with the Dexcom G7 Continuous Glucose Monitoring (CGM) Syste...
|
| Per Share |
Current |
| Earnings (TTM) |
-1.46 $ |
| Revenues (TTM) |
14.38 $
|
| Cash Flow (TTM) |
0.16 $ |
| Cash |
6.71 $
|
| Book Value |
4.03 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.46 $
|
| Revenues (TTM) |
14.38 $ |
| Cash Flow (TTM) |
0.16 $ |
| Cash |
6.71 $
|
| Book Value |
4.03 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| United States |
|
 70.45 % |
of total Revenue |
| Outside the United States |
|
29.68 % |
of total Revenue |
| Pump |
|
47.12 % |
of total Revenue |
| Supplies and other |
|
52.59 % |
of total Revenue |
| Net revenue recognized deferred for Tandem Choice program |
|
0.43 % |
of total Revenue |
| |
On February 21 2024 the Tandem Diabetes Care Inc provided following guidance
insulin pump, in select international markets. Completed the acquisition of TypeZero Technologies, Inc., enhancing Tandem's automated insulin delivery technology.
Revenue for the quarter ended December 31, 2023, was $200 million, representing a 15% increase compared to the same period in 2022. Gross margin for the quarter was 55%, while operating expenses were $80 million.
For the full year 2023, Tandem reported total revenue of $750 million, a 20% increase from 2022. The company also achieved a gross margin of 56% for the year, with operating expenses totaling $300 million.
Looking ahead to 2024, Tandem Diabetes Care expects continued growth, with projected revenue of $1 billion. The co...
|
|
|
24.46%